Nothing can hinder the integrity of research efforts like contamination or misidentification. Explore the real-life effects when research materials are not authenticated and the steps we can take to establish best practices in the laboratory.
Organoids are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research. These 3-D models are becoming more relevant because they are predictive of the in vivo tumor microenvironment. In efforts to simplify Organoid culture, ATCC has developed Organoid Growth Kits which comprise single-use supplements created to streamline media preparation.
These kits contain the most costly and cumbersome supplements and reagents, reducing the time and effort required to prepare media and ensuring the successful growth of your organoids.
Diabetes impacts over 500 million people globally, highlighting the urgent need for innovative therapies that can improve patient outcomes. Pluripotent stem cells (PSCs) offer remarkable potential in regenerative medicine by enabling the development of functional beta islet cell s- paving the way for transformative treatments for this widespread disease.
Charles Rosser has developed Oncuria®, a bladder cancer test using Luminex® xMAP® Technology to detect 10 glycoproteins with 93% sensitivity and up to 95% specificity. It aids in early detection, monitoring, and predicting response to immunotherapy. Now available as a laboratory-developed test (LDT), Oncuria® has received FDA Breakthrough Device Designation, representing a major advance in bladder cancer care.
In this webinar, “Methods and Reagents for Culturing and Characterizing Organoids and Cancer Spheroids”, we demonstrate techniques to culture and perform high-throughput analysis of multiple organoid and cancer models.
Click here to visit ATCC's podcast page: https://www.atcc.org/resources/podcasts